Actinium Pharmaceuticals Net Income
| ATNM Stock | USD 1.12 0.01 0.90% |
As of the 16th of February 2026, Actinium Pharmaceuticals shows the Standard Deviation of 3.83, mean deviation of 2.9, and Risk Adjusted Performance of (0.03). Actinium Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Actinium Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Actinium Pharmaceuticals is priced correctly, providing market reflects its regular price of 1.12 per share. Given that Actinium Pharmaceuticals is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Actinium Pharmaceuticals Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 1.7 K | Revenue | Earnings Share (1.11) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -34.4 M | -32.7 M | |
| Net Loss | -34.4 M | -36.1 M | |
| Net Loss | -29.7 M | -31.2 M | |
| Net Loss | (1.14) | (1.20) |
Actinium | Net Income | Build AI portfolio with Actinium Stock |
Evaluating Actinium Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Actinium Pharmaceuticals's fundamental strength.
Latest Actinium Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Actinium Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Actinium Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Actinium Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Actinium Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actinium Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (38.24 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Actinium Net Income Regression Statistics
| Arithmetic Mean | (23,265,626) | |
| Geometric Mean | 10,073,674 | |
| Coefficient Of Variation | (55.53) | |
| Mean Deviation | 9,244,378 | |
| Median | (24,322,000) | |
| Standard Deviation | 12,919,856 | |
| Sample Variance | 166.9T | |
| Range | 48.8M | |
| R-Value | (0.87) | |
| Mean Square Error | 43.5T | |
| R-Squared | 0.76 | |
| Slope | (2,224,502) | |
| Total Sum of Squares | 2670.8T |
Actinium Net Income History
Other Fundumenentals of Actinium Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Actinium Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Actinium Pharmaceuticals is extremely important. It helps to project a fair market value of Actinium Stock properly, considering its historical fundamentals such as Net Income. Since Actinium Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actinium Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actinium Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value - what Actinium Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Actinium Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Actinium Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Actinium Pharmaceuticals.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Actinium Pharmaceuticals on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Actinium Pharmaceuticals or generate 0.0% return on investment in Actinium Pharmaceuticals over 90 days. Actinium Pharmaceuticals is related to or competes with PDS Biotechnology, Xilio Development, Tempest Therapeutics, OnKure Therapeutics, Reviva Pharmaceuticals, Kezar Life, and Tvardi Therapeutics. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing th... More
Actinium Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Actinium Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Actinium Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 5.84 |
Actinium Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Actinium Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Actinium Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Actinium Pharmaceuticals historical prices to predict the future Actinium Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.44) |
Actinium Pharmaceuticals February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.9 | |||
| Coefficient Of Variation | (1,889) | |||
| Standard Deviation | 3.83 | |||
| Variance | 14.67 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 20.75 | |||
| Value At Risk | (5.43) | |||
| Potential Upside | 5.84 | |||
| Skewness | 0.9669 | |||
| Kurtosis | 2.05 |
Actinium Pharmaceuticals Backtested Returns
Actinium Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.097, which signifies that the company had a -0.097 % return per unit of risk over the last 3 months. Actinium Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Actinium Pharmaceuticals' Risk Adjusted Performance of (0.03), standard deviation of 3.83, and Mean Deviation of 2.9 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Actinium Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Actinium Pharmaceuticals is expected to be smaller as well. At this point, Actinium Pharmaceuticals has a negative expected return of -0.33%. Please make sure to confirm Actinium Pharmaceuticals' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Actinium Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.56 |
Good reverse predictability
Actinium Pharmaceuticals has good reverse predictability. Overlapping area represents the amount of predictability between Actinium Pharmaceuticals time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Actinium Pharmaceuticals price movement. The serial correlation of -0.56 indicates that roughly 56.0% of current Actinium Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.56 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Actinium Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Actinium Pharmaceuticals reported net income of (38.24 Million). This is 111.21% lower than that of the Biotechnology sector and 154.6% lower than that of the Health Care industry. The net income for all United States stocks is 106.7% higher than that of the company.
Actinium Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actinium Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actinium Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Actinium Pharmaceuticals by comparing valuation metrics of similar companies.Actinium Pharmaceuticals is currently under evaluation in net income category among its peers.
Actinium Fundamentals
| Return On Equity | -1.33 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (63.24) % | ||||
| Current Valuation | (17.62 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Shares Owned By Insiders | 2.36 % | ||||
| Shares Owned By Institutions | 21.28 % | ||||
| Number Of Shares Shorted | 1.04 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 384.75 X | ||||
| Gross Profit | 90 K | ||||
| EBITDA | (37.43 M) | ||||
| Net Income | (38.24 M) | ||||
| Cash And Equivalents | 116.33 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 1.57 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 18.83 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (33.07 M) | ||||
| Short Ratio | 7.94 X | ||||
| Earnings Per Share | (1.11) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 25 | ||||
| Beta | -0.3 | ||||
| Market Capitalization | 34.63 M | ||||
| Total Asset | 76.9 M | ||||
| Retained Earnings | (375.83 M) | ||||
| Working Capital | 66.36 M | ||||
| Current Asset | 26.48 M | ||||
| Current Liabilities | 4.61 M | ||||
| Net Asset | 76.9 M |
About Actinium Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actinium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actinium Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actinium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Actinium diversify its offerings? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Actinium Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Actinium Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Actinium's accounting equity. The concept of intrinsic value - what Actinium Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Actinium Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Actinium Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actinium Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Actinium Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.